Condition: Breast Cancer, Metastatic · Breast Cancer Invasive · Breast Cancer Early Stage Breast Cancer (Stage 1-3) · Sponsor: ScreenCell
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
This description comes directly from the study's public registry record.
Jessica GROULT, Ph.D · 0033669645318 · jgroult@screencell.com
Sina NASERIAN, Ph.D · snaserian@screencell.com
Always discuss trial participation with your own doctor first.
| CMC Ambroise Paré Hartmann | Neuilly-sur-Seine, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06807502